Company intelligence / Profile preview

Surv BioPharma

Kagoshima, Kagoshima, Japan

Ownership: Private
Employees: ~11
Development stage: Other

Overview

Surv.m-CRA-1, a survivin promoter-driven oncolytic virus, showed highly favorable efficacy and safety in a Phase II trial for primary malignant bone tumors in Japan; preparing to initiate Phase III in October 2025 aiming for full regulatory approval by 2027. Surv.m-CRA-2-IC is at the non-clinical stage and incorporates immunogenes for systemic anti-tumor activity[5].

Therapeutic areas: Oncology
Modalities: Oncolytic virus therapyGene therapy
Industry: Biotech

Drug pipeline

5 assets

Ad-HGF/HB-EGF

Approved

4 more assets in the full pipeline.

Request access →

Partnerships

Nippon Zoki Pharmaceutical (Japan, exclusive license for Surv.m-CRA-1 in bone/soft tissue tumors) [5]

Beyond the preview

Go deeper on Surv BioPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Surv BioPharma.

Explore the full profile